Markus Vogt, Nevenka Dudvarski Stankovic, Yiliam Cruz Garcia, Julia Hofstetter, Katharina Schneider, Filiz Kuybu, Theresa Hauck, Bikash Adhikari, Anton Hamann, Yamila Rocca, Lara Grysczyk, Benedikt Martin, Anneli Gebhardt-Wolf, Armin Wiegering, Markus Diefenbacher, Georg Gasteiger, Stefan Knapp, Dieter Saur, Martin Eilers, Mathias Rosenfeldt, Florian Erhard, Seychelle M Vos, Elmar Wolf
OBJECTIVE: The hallmark oncogene MYC drives the progression of most tumours, but direct inhibition of MYC by a small-molecule drug has not reached clinical testing. MYC is a transcription factor that depends on several binding partners to function. We therefore explored the possibility of targeting MYC via its interactome in pancreatic ductal adenocarcinoma (PDAC). DESIGN: To identify the most suitable targets among all MYC binding partners, we constructed a targeted shRNA library and performed screens in cultured PDAC cells and tumours in mice...
May 31, 2024: Gut